Suppr超能文献

17-β-羟甾脱氢酶 13 定位在脂滴上的结构基础。

Structural basis of lipid-droplet localization of 17-beta-hydroxysteroid dehydrogenase 13.

机构信息

Medicine Design, Pfizer Inc, Groton, CT, 06340, USA.

Medicine Design, Pfizer Inc, Cambridge, MA, 02139, USA.

出版信息

Nat Commun. 2023 Aug 24;14(1):5158. doi: 10.1038/s41467-023-40766-0.

Abstract

Hydroxysteroid 17-beta-dehydrogenase 13 (HSD17B13) is a hepatic lipid droplet-associated enzyme that is upregulated in patients with non-alcoholic fatty liver disease. Recently, there have been several reports that predicted loss of function variants in HSD17B13 protect against the progression of steatosis to non-alcoholic steatohepatitis with fibrosis and hepatocellular carcinoma. Here we report crystal structures of full length HSD17B13 in complex with its NAD cofactor, and with lipid/detergent molecules and small molecule inhibitors from two distinct series in the ligand binding pocket. These structures provide insights into a mechanism for lipid droplet-associated proteins anchoring to membranes as well as a basis for HSD17B13 variants disrupting function. Two series of inhibitors interact with the active site residues and the bound cofactor similarly, yet they occupy different paths leading to the active site. These structures provide ideas for structure-based design of inhibitors that may be used in the treatment of liver disease.

摘要

羟甾体 17-β-脱氢酶 13(HSD17B13)是一种与肝脂滴相关的酶,在非酒精性脂肪性肝病患者中上调。最近有几项报道表明,HSD17B13 的预测功能丧失变异体可防止脂肪变性向伴有纤维化和肝细胞癌的非酒精性脂肪性肝炎进展。在这里,我们报告了全长 HSD17B13 与 NAD 辅酶、脂/去污剂分子以及来自两个不同系列的小分子抑制剂在配体结合口袋中的复合物的晶体结构。这些结构提供了有关脂滴相关蛋白作为锚定到膜的机制的见解,以及 HSD17B13 变体破坏功能的基础。两种系列的抑制剂与活性位点残基和结合的辅酶相似地相互作用,但它们占据了通向活性位点的不同路径。这些结构为基于结构的抑制剂设计提供了思路,这些抑制剂可用于治疗肝脏疾病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca21/10449848/94f0d9290a3e/41467_2023_40766_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验